This study is for people with Glioblastoma (GBM), a type of brain tumor, who are starting treatment with Optune. Optune uses electrical fields (called Tumor Treating Fields or TTFields) to fight cancer. This research aims to see if a more precise way of mapping the Optune device onto your head, using advanced MRI scans called "whole brain spectroscopy imaging," works better than the standard mapping method. To join, you must be at least 22 years old, have a confirmed GBM diagnosis, and have already had surgery and radiation therapy. The main goal is to see how long it takes for the tumor to grow or spread, measured every two months. The study is currently recruiting 155 participants, but its overall status is unclear.

Study design

This is an interventional study planning to enroll 155 participants. It compares two ways of mapping the Optune device for Glioblastoma patients.

What's involved

All participants will receive whole brain spectroscopy imaging as part of their MRI scans. Participants will either receive standard Optune mapping or an alternative, more precise mapping.

Compensation

Not stated in the trial record.

Follow-up

The study measures how long it takes for the tumor to progress, with assessments every two months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.